<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>PURPOSE: Patients (pts.) with <z:hpo ids='HP_0005110'>atrial fibrillation</z:hpo> (AF) and atrial <z:e sem="disease" ids="C0087086" disease_type="Disease or Syndrome" abbrv="">thrombi</z:e> are known to have an increased risk for <z:e sem="disease" ids="C0007780" disease_type="Disease or Syndrome" abbrv="">cerebral embolism</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>However, little is known about the clinical course of atrial <z:e sem="disease" ids="C0087086" disease_type="Disease or Syndrome" abbrv="">thrombi</z:e> and the incidence of <z:e sem="disease" ids="C0007780" disease_type="Disease or Syndrome" abbrv="">cerebral embolism</z:e> in those patients during anticoagulation therapy </plain></SENT>
<SENT sid="2" pm="."><plain>The high sensitivity of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MR</z:e> imaging (MRI) including diffusion-weighted imaging (DWI) suggests that this technique could provide an improved estimate of <z:e sem="disease" ids="C0007780" disease_type="Disease or Syndrome" abbrv="">cerebral embolism</z:e> associated with the presence of left atrial <z:e sem="disease" ids="C0087086" disease_type="Disease or Syndrome" abbrv="">thrombi</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>The aims of this prospective study were to evaluate 1) the prevalence of clinically silent and apparent <z:e sem="disease" ids="C0007780" disease_type="Disease or Syndrome" abbrv="">cerebral embolism</z:e> in pts. with newly diagnosed AF and atrial <z:e sem="disease" ids="C0087086" disease_type="Disease or Syndrome" abbrv="">thrombi</z:e> using MRI/DWI, 2) the long-term fate of atrial <z:e sem="disease" ids="C0087086" disease_type="Disease or Syndrome" abbrv="">thrombi</z:e> under continues anticoagulation therapy and 3) the incidence of <z:e sem="disease" ids="C0007780" disease_type="Disease or Syndrome" abbrv="">cerebral embolism</z:e> during a follow-up period of 12 months with continuous anticoagulation therapy </plain></SENT>
<SENT sid="4" pm="."><plain>MATERIALS AND METHODS: The study group consisted of 32 pts. with 1) newly diagnosed AF and evidence of left atrial (LA) <z:e sem="disease" ids="C0087086" disease_type="Disease or Syndrome" abbrv="">thrombi</z:e> detected by TEE and 2) a new start of anticoagulation therapy [International Normalized Ratio (INR) 2.0 - 3.0] </plain></SENT>
<SENT sid="5" pm="."><plain>19 pts. with 1) newly diagnosed AF and no evidence of atrial <z:e sem="disease" ids="C0087086" disease_type="Disease or Syndrome" abbrv="">thrombi</z:e> and 2) an equivalent anticoagulation regimen served as the control group </plain></SENT>
<SENT sid="6" pm="."><plain>In both groups a) MRI/DWI studies of the brain (weeks 0, 4, 8, 12, 20, 28, 36, 44, and 52), b) transesophageal echocardiographic studies (TEE) for assessment of LA-<z:e sem="disease" ids="C0087086" disease_type="Disease or Syndrome" abbrv="">Thrombi</z:e> (weeks 0 and 52) and c) clinical neurological assessments (weeks 0, 20 and 52) were performed </plain></SENT>
<SENT sid="7" pm="."><plain>RESULTS: In the study group (AF and LA-<z:e sem="disease" ids="C0087086" disease_type="Disease or Syndrome" abbrv="">Thrombi</z:e>) 11 out of 32 pts </plain></SENT>
<SENT sid="8" pm="."><plain>(34 %) displayed signs of <z:hpo ids='HP_0011009'>acute</z:hpo> (n = 8) or <z:hpo ids='HP_0011010'>chronic</z:hpo> (n = 3) <z:e sem="disease" ids="C0007780" disease_type="Disease or Syndrome" abbrv="">cerebral embolism</z:e> in the initial MRI studies </plain></SENT>
<SENT sid="9" pm="."><plain>In 4 out of 32 pts </plain></SENT>
<SENT sid="10" pm="."><plain>(13 %), MRI/DWI depicted new or additional <z:e sem="disease" ids="C0007780" disease_type="Disease or Syndrome" abbrv="">cerebral emboli</z:e> (n = 12) during the follow-up period despite continuous anticoagulation therapy </plain></SENT>
<SENT sid="11" pm="."><plain>2 (n = 2/4; 50 %) of these patients had clinically apparent neurological deficits </plain></SENT>
<SENT sid="12" pm="."><plain>In the control group 1 out of 19 pts </plain></SENT>
<SENT sid="13" pm="."><plain>(5 %) showed evidence of <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:e sem="disease" ids="C0007780" disease_type="Disease or Syndrome" abbrv="">cerebral embolism</z:e> as assessed by MRI/DWI at the beginning of the study (week 0) </plain></SENT>
<SENT sid="14" pm="."><plain>No embolic <z:e sem="disease" ids="C0221505" disease_type="Disease or Syndrome" abbrv="">cerebral lesions</z:e> were detected during the 12-month follow-up </plain></SENT>
<SENT sid="15" pm="."><plain>Within 12 months only 63 % (n = 20/32) of LA <z:e sem="disease" ids="C0087086" disease_type="Disease or Syndrome" abbrv="">thrombi</z:e> in the study group resolved completely under anticoagulation </plain></SENT>
<SENT sid="16" pm="."><plain>CONCLUSION: 1 </plain></SENT>
<SENT sid="17" pm="."><plain>The incidence of clinically inapparent <z:e sem="disease" ids="C0007780" disease_type="Disease or Syndrome" abbrv="">cerebral emboli</z:e> in pts. with newly diagnosed AF and atrial <z:e sem="disease" ids="C0087086" disease_type="Disease or Syndrome" abbrv="">thrombi</z:e> is much higher than the incidence of clinically apparent emboli and has been underestimated in the past </plain></SENT>
<SENT sid="18" pm="."><plain>2 </plain></SENT>
<SENT sid="19" pm="."><plain>New <z:e sem="disease" ids="C0007780" disease_type="Disease or Syndrome" abbrv="">cerebral embolism</z:e> may occur even with continued effective anticoagulation therapy in 13 % of pts </plain></SENT>
<SENT sid="20" pm="."><plain>3 </plain></SENT>
<SENT sid="21" pm="."><plain>Only 63 % of atrial <z:e sem="disease" ids="C0087086" disease_type="Disease or Syndrome" abbrv="">thrombi</z:e> resolve completely within 12 months under anticoagulation therapy </plain></SENT>
</text></document>